Skip to main content
SpringerLink
Log in

Sonografie bei Verdacht auf Leberkrebs

Diagnose geht auch ohne Biopsie

  • Gastroonkologie
  • Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Nicht wenige Patienten in der Hausarztpraxis haben ein erhöhtes Risiko, an einem hepatozellulären Karzinom zu erkranken. Diese sollten identifiziert und halbjährlich per Ultraschall gescreent werden. Dabei ist heutzutage eine sichere Diagnose auch ohne Biopsie möglich — dank kontrastverstärkter Bildgebung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  Google Scholar 

  2. World Health Organization: World cancer statistics 2012.

  3. Bouattour M et al. Recent Developments of c-Met as a Therapeutic Target in Hepatocellular Carcinoma. Hepatology. 2018;67(3):1132–49.

    Article  Google Scholar 

  4. Tanaka Y et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002; 99(24):15584–9.

    Article  CAS  Google Scholar 

  5. Cramp ME et al. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol. 2014; 14:137.

    Article  Google Scholar 

  6. Rahman R et al. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol. 2013;5(9):186–94.

    Article  Google Scholar 

  7. S3-Leitlinie „Hepatozelluläres Karzinom“, AWMF-Registernummer 032/053OL.

  8. Claudon M et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34(1):11–29.

    CAS  PubMed  Google Scholar 

  9. Leoni S et al. Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? Ultraschall Med. 2013;34(3):280–7.

    Article  CAS  Google Scholar 

  10. Friedrich-Rust M et al. Contrast-Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a metaanalysis. Liver Int. 2013;33(5):739–55.

    Article  CAS  Google Scholar 

  11. Oken M et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.

    Article  CAS  Google Scholar 

  12. Greten TF, Manns MP. Hepatocellular carcinoma — diagnosis and treatment. Dtsch Med Wochenschr. 2008;133:1907–10.

    Article  CAS  Google Scholar 

  13. Schellhaas B et al. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol. 2017;29(9):1036–44.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik 1, Ulmenweg 18, D-91054, Erlangen, Deutschland

    Barbara Schellhaas

Authors
  1. Barbara Schellhaas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara Schellhaas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schellhaas, B. Diagnose geht auch ohne Biopsie. Im Focus Onkologie 21, 65–66 (2018). https://doi.org/10.1007/s15015-018-3911-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-3911-4

Search

Navigation